Media & Press

For media inquiries, please contact media@phenomixsciences.com

PHENOMIX AND MAYO CLINIC DETERMINE OBESITY RISK THROUGH PHENOTYPES

July 1, 2021

Using one patient blood sample, the MyPhenome test developed by Mayo Clinic employs an artificial intelligence-based algorithm to analyze a patient’s DNA as well as metabolomic and hormone markers related to obesity. The companies expect it to help clinicians provide earlier diagnosis and better anti-obesity treatment options, including drugs, devices, or surgeries, by analyzing the phenotypes identified from the test. Continue Reading...

Phenomix Sciences taps Mayo Clinic tech for AI-powered obesity diagnostic

May 5, 2021

In a Mayo Clinic logo shift from traditional thinking that lumps together all cases of obesity, researchers are increasingly proving that a combination of genetic and environmental factors have resulted in several distinct forms of the condition, each requiring a different treatment. Continue Reading...

Phenomix Sciences Signs Exclusive Technology Licensing Deal With Mayo Clinic for Obesity Phenotype Blood Test

May 4, 2021

ST. PAUL, Minn.--(BUSINESS WIRE)--Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes. The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels. Its AI-driven algorithmic solution identifies four specific obesity phenotypes to give doctors the ability to prescribe more precise anti-obesity treatments. With the finalization of the CLIA lab underway, Phenomix anticipates launching the MyPhenome™ test before the end of 2021. Continue Reading...

Phenomix, Mayo Clinic Ink Licensing Deal for Obesity Phenotype Blood Test

May 4, 2021

NEW YORK – Biomedical startup company Phenomix Sciences said on Tuesday that it has signed an exclusive technology licensing agreement with the Mayo Clinic for a blood test to predict obesity phenotypes. Financial and other terms of the deal were not disclosed. The multiomics MyPhenome test uses technology developed at the Mayo Clinic to analyze a person's genomic, metabolomic, and hormone profile, and uses artificial intelligence-driven algorithms to identify which one of four specific obesity phenotypes the person fits: Hungry Brain, a defect of satiation; Hungry Gut, a defect of satiety; Emotional Hunger, emotional reward from eating; or Slow Burn, a defect in energy expenditure. Continue Reading...

Q&A: How new blood testing could help doctors better treat obesity

May 3, 2021

Phenomix Sciences was founded by National Institutes of Health (NIH)-funded obesity experts and Mayo Clinic physician-scientists Andres Acosta, MD, PhD, and Michael Camilleri, MD, in Rochester, Minnesota, in 2017. Health2047, the wholly-owned innovation subsidiary of the AMA created to overcome systemic dysfunction in the U.S. health care, recently launched the company. Continue Reading...

Novel obesity classifications can aid in tailoring weight-loss treatments

April 28, 2021

Phenotype-guided obesity interventions, determined by a blood test, can double weight loss for patients compared with standard obesity care, according to a presenter at the Obesity Medicine Association 2021 virtual conference.

AMA unit Health2047 spins out obesity testing startup to accelerate personalized medicine

April 1, 2021

The American Medical Association innovation subsidiary Health2047 has spun off a company that uses personalized medicine to fight obesity. Phenomix Sciences is a phenotype testing company that carries out the AMA’s mission to confront chronic diseases such as obesity. Phenomix uses a blood test called MyPhenome that it has licensed from the Mayo Clinic to allow doctors to prescribe individualized therapies. MyPhenome measures DNA as well as a person’s metabolites and hormones. These biomarkers make up a person’s phenotype, according to Phenomix. Continue Reading...

Health2047 Spins Out Obesity Testing Company Phenomix Sciences

March 22, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Health2047 Inc., the Silicon Valley-based innovation subsidiary of the American Medical Association (AMA), today announced the spin out of Phenomix Sciences (Phenomix), a phenotype testing company whose AI-derived test analyzes genomics, metabolomics and hormone levels to deliver a new personalized measure for obesity that enhances treatment outcomes. Phenomix provides a solution that identifies four specific obesity phenotypes; the company’s MyPhenome^TM test gives doctors the ability to prescribe individualized anti-obesity therapies that are more effective. Continue Reading...